To provide for research and education with respect to uterine fibroids, and for other purposes.
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
The Stephanie Tubbs Jones Uterine Fibroid Research and Education Act of 2025 addresses the significant under-researched public health burden of uterine fibroids, which affect up to 77% of women by menopause and disproportionately impact Black women (80% prevalence vs. 70% in White women). The bill authorizes million annually (FY2026-2030) for NIH-coordinated fibroid research; establishes or expands a Medicaid/CHIP research database to collect fibroid treatment data; requires HHS to develop and disseminate public education on fibroid awareness, racial disparities, and non-hysterectomy treatment options; and directs HHS to work with medical societies to promote evidence-based care. A congressional report on Medicaid/CHIP expenditures for fibroid treatment is required within 2 years.
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers.
At a Glance
What This Bill Does
Expand research, education, and data collection with respect to uterine fibroids, which affect an estimated 26 million American women, with focus on racial and ethnic disparities in diagnosis, treatment, and outcomes.
Who Benefits
- Women with uterine fibroids
- Minority women (especially Black women)
- Researchers in women's health
Who Bears Costs
- Federal government (research appropriations)
- NIH (coordination)
- HHS (education and reporting)
Key Policy Areas
Healthcare, Medical Research
Primary Purpose
Expand research, education, and data collection with respect to uterine fibroids, which affect an estimated 26 million American women, with focus on racial and ethnic disparities in diagnosis, treatment, and outcomes.
Policy Domains
Legislative Strategy
"Combine federal research funding with public education and healthcare provider outreach to address under-diagnosis, racial disparities, and over-reliance on hysterectomy for fibroid treatment"
Legislative Progress
IntroducedMr. Booker introduced the following bill; which was read twice …
Stakeholder Effects
cui bono?How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.
Manufacturers of non-hysterectomy fibroid treatments, Minority women with fibroids, Women and minority populations at risk for fibroids
HHS data collection systems, HHS public education programs
Key Definitions
Terms defined in this bill
Members of a racial and ethnic minority group as defined in section 1707(g) of the Public Health Service Act
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology